David Weill - 20 May 2026 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Reporting relationship
Director
Issuer ticker
TMDX
Reported as of
20 May 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
22 May 2026, 16:15:19 UTC
Prior SEC filing
06 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: /s/ Gerardo Hernandez, Attorney-in-Fact

Key filing fact

David Weill filed Form 4 for TransMedics Group, Inc. (TMDX) on 22 May 2026.

Key facts

  • This page summarizes David Weill's Form 4 filing for TransMedics Group, Inc. (TMDX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 22 May 2026, 16:15.

Change

  • Previous filing in this sequence was filed on 06 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001774270 Primary reporting owner

Weill David

Relationship
Director
Address
C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER
Signature
By: /s/ Gerardo Hernandez, Attorney-in-Fact
Signature date
22 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMDX transaction

Common Stock

Award

Transaction value
Shares
+2,922
Change %
+24%
Price
$0.000000*
Shares after
15,056
Date
20 May 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .